London, UK, September 7, 2026
GSK plc has submitted a regulatory application in the European Union for a next-generation, lower-carbon version of Ventolin (salbutamol) metered dose inhaler (MDI), marking another step in the company’s efforts to reduce the environmental impact of respiratory medicines while maintaining established treatment performance. The proposed inhaler uses a lower-global-warming-potential propellant and is designed to provide the same established active medicine, salbutamol, in a new formulation and device configuration. The submission forms part of GSK’s broader strategy to transition its pressurised metered dose inhaler portfolio toward lower-carbon propellants, an area that has become increasingly important as pharmaceutical manufacturers address greenhouse-gas emissions associated with inhaler technologies. The company emphasized that the product remains subject to regulatory review and approval and is not yet authorized for use in the EU.
GSK Advances Lower-Carbon Inhaler Technology
Ventolin (salbutamol) is an established short-acting bronchodilator used to provide rapid relief of bronchospasm and asthma symptoms. Traditional pressurised MDIs rely on hydrofluoroalkane propellants, which can have a significant greenhouse-gas impact. GSK’s next-generation product is intended to replace the existing propellant technology with a lower-carbon alternative, substantially reducing the inhaler’s global-warming potential while preserving the delivery of salbutamol to patients. This approach is significant because the environmental footprint of respiratory care extends beyond the active pharmaceutical ingredient itself, with inhaler propellants representing an important source of emissions. GSK has been developing lower-carbon respiratory products as part of its sustainability strategy, recognizing that changing the propellant in an established MDI requires extensive pharmaceutical development, device engineering, manufacturing validation and regulatory assessment. The company has indicated that the next-generation Ventolin MDI is designed to maintain the familiar therapeutic purpose of the existing product while introducing a substantially lower-impact propellant. Such development requires demonstrating that the new inhaler consistently delivers the appropriate dose and aerodynamic performance while meeting applicable quality, safety and efficacy requirements.
Regulatory Submission Supports Sustainable Respiratory Care
The EU regulatory filing represents an important milestone because transitioning an established inhaler to a new propellant is not simply a packaging change. The reformulated product must undergo appropriate regulatory evaluation, including assessment of pharmaceutical quality, inhaler performance and clinical considerations relevant to the proposed product. GSK’s submission therefore demonstrates how sustainability objectives can be incorporated into the development of widely used medicines without changing the therapeutic molecule itself. The lower-carbon Ventolin initiative also reflects a broader transformation underway across the respiratory pharmaceutical industry. Pharmaceutical companies are exploring new propellants and inhaler technologies that can reduce greenhouse-gas emissions while maintaining reliable drug delivery. For patients who depend on inhalers, the challenge is to achieve environmental improvements without compromising dose consistency, usability, product quality or clinical performance. GSK’s regulatory strategy illustrates the technical complexity involved in making such changes at scale. The company has previously announced progress toward transitioning its respiratory portfolio to next-generation propellants and has identified MDI decarbonization as a key component of its environmental strategy. Because inhalers are used by millions of patients worldwide, even incremental reductions in the carbon footprint of an individual device could have meaningful cumulative environmental benefits when implemented across large patient populations.
Advertisement
Next-Generation Ventolin Could Reduce Inhaler Emissions
If authorized, the new Ventolin MDI could provide patients with access to an established salbutamol rescue medicine delivered through a significantly lower-carbon inhaler platform. The potential environmental benefit is particularly relevant for healthcare systems seeking to reduce emissions across their supply chains while continuing to provide essential respiratory treatments. For the pharmaceutical industry, the filing highlights the growing intersection between drug development, inhaler technology, regulatory science and sustainability. Reformulating an established medicine around a lower-impact propellant requires coordinated work across formulation development, device design, analytical testing, manufacturing, quality control and regulatory affairs. GSK’s EU submission demonstrates how these disciplines can converge to address both patient needs and environmental objectives. The application will now undergo the applicable European regulatory review process. Until authorization is granted, the proposed lower-carbon Ventolin remains an investigational regulatory submission rather than an approved EU product. If approved, it could represent an important step toward reducing the environmental footprint of widely used pressurised metered dose inhalers while preserving access to a familiar respiratory medicine.
Source: GSK press release
